Frontier Clinical Research, LLC | Scottdale, PA

Research site

(Unclaimed)

Location

109 Crossroads Road Suite 301, Scottdale, Pennsylvania, United States of America

Site insights

Top conditions

Top treatments

Lasmiditan

Relamorelin

LY573144

Linaclotide

Tenapanor

Elismetrep

LY3457263

Baloxavir Marboxil

Tiotropium

LY3502970

Parent organization

This site is a part of Frontier Clinical Research, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 23 total trials

New

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.

Begins enrollment this month

Acute Migraine

Drug: Placebo

Drug: Elismetrep

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabete...

Enrolling

Type 2 Diabetes

Drug: LY3457263

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with plac...

Begins enrollment this month

Migraine

Drug: Placebo

Drug: Elismetrep

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lym...

Enrolling

Lyme Disease

Biological: VLA15

Biological: Placebo

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

Invitation-only

Irritable Bowel Syndrome With Constipation (IBS-C)

Drug: Tenapanor

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediat...

Active, not recruiting

Irritable Bowel Syndrome With Constipation (IBS-C)

Drug: Tenapanor 50 MG

Drug: Placebo